Titre:
  • Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Auteur:Lambertini, Matteo; Martel, Samuel; Campbell, Christine; Guillaume, Sébastien; Hilbers, Florentine FS; Schuehly, Uwe; Korde, Larissa; Abdel Azim, Hatem Hamdy; Di Cosimo, Serena; Tenglin, Richard RC; Huober, Jens; Baselga, José; Moreno-Aspitia, Alvaro; Piccart-Gebhart, Martine; Gelber, Richard D; de Azambuja, Evandro; Ignatiadis, Michail
Informations sur la publication:Cancer
Statut de publication:Publié, 2018-10-01
Sujet CREF:Cancérologie
Médecine pathologie humaine
Sciences bio-médicales et agricoles
Mots-clés:breast cancer
human epidermal growth factor receptor 2 (HER2)-positive
lapatinib
pregnancy
survivorship
trastuzumab
young patients
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0008-543X
info:doi/10.1002/cncr.31784
info:scp/85055259280
info:pmid/30335191